one
key
point
understand
ang
ii
one
member
famili
angiotensin
peptid
produc
ra
ang
ii
consist
eight
amino
acid
like
peptid
free
amino
group
one
end
free
carboxyl
group
ang
ii
also
denot
first
amino
acid
eighth
amino
acid
therefor
cleavag
amino
acid
either
end
ang
ii
molecul
gener
smaller
peptid
fragment
fig
exampl
remov
amino
acid
result
gener
peptid
consist
seven
amino
acid
start
second
amino
acid
ang
ii
denot
histor
also
known
ang
iii
fragment
gener
ang
ii
three
known
physiolog
relev
two
deriv
cleavag
ang
iii
ang
iv
one
form
cleavag
singl
amino
acid
ang
iii
form
follow
cleavag
bond
ang
ii
aminopeptidas
ang
iv
form
cleavag
ang
iii
aminopeptidas
b
n
ang
iii
share
mani
properti
ang
ii
pressor
activ
aldosteron
stimul
activ
ang
iv
distinct
receptor
central
nervou
system
effect
togeth
oppos
action
ang
ii
gener
cleavag
either
ang
ii
ang
focu
much
research
sinc
discoveri
biolog
function
oppos
ang
ii
interest
altern
compon
ra
year
two
group
independ
discov
enzym
similar
ace
human
tissu
homolog
ace
initi
call
hace
subsequ
name
angiotensin
convert
enzym
although
structur
similar
ace
differ
substrat
affin
resist
inhibit
ace
inhibitor
like
ace
transmembran
protein
consist
amino
acid
singl
transmembran
portion
extern
portion
contain
catalyt
activ
enzym
intern
inact
section
transmembran
proteinas
adam
act
sheddas
releas
activ
enzym
extracellular
environ
fig
releas
solubl
carboxypeptidas
capabl
cleav
singl
amino
acid
variou
substrat
includ
ang
ii
ang
neurotensin
kinetensin
see
review
burrel
colleagu
importantli
gener
directli
ang
ii
indirectli
cleav
ang
inact
intermedi
fragment
cleav
ace
produc
fig
two
pathway
convers
ang
ii
kinet
favour
compar
convers
ang
addit
role
altern
ra
transmembran
protein
interestingli
identifi
receptor
site
spike
protein
sever
acut
respiratori
syndrom
sar
coronaviru
therebi
facilit
infect
target
cell
much
work
carri
anim
date
peptid
shown
antihypertens
cardioprotect
properti
well
properti
vascular
endotheli
cell
smooth
muscl
cell
cardiac
myocyt
cardiac
fibroblast
contrast
ang
ii
also
properti
result
studi
propos
repres
effector
peptid
counterbalanc
arm
ra
capabl
oppos
deleteri
action
ang
ii
put
receptor
g
receptor
encod
ma
although
receptor
may
well
exist
thu
togeth
ma
receptor
repres
altern
arm
axi
ra
may
present
counterbalanc
system
deleteri
aceang
axi
fig
clearli
hold
central
role
ra
influenc
axe
capabl
simultan
degrad
ang
ii
gener
fig
angiotensin
convert
enzym
known
particip
activ
system
degrad
bradykinin
fig
inhibitor
ace
therefor
lead
accumul
bradykinin
may
contribut
antihypertens
properti
drug
well
observ
chronic
cough
angioedema
liver
bradykinin
bind
receptor
caus
increas
hepat
resist
elev
portal
pressur
vascular
bed
bradykinin
induc
vasodilat
bind
receptor
shown
induc
relax
porcin
coronari
arteri
possibl
explan
ace
inhibitori
properti
prevent
degrad
bradykinin
recent
year
scientist
depart
tradit
held
view
ra
exclus
circul
endocrin
system
realiz
mani
organ
heart
kidney
liver
pancrea
constitut
express
classic
ra
compon
requir
function
autonom
ra
local
gener
angiotensin
peptid
fragment
demonstr
multitud
action
implic
cell
growth
cell
prolifer
apoptosi
reactiv
oxygen
speci
gener
inflamm
fibrogenesi
although
conceptu
separ
local
ra
system
ra
must
interact
final
peptid
product
depend
interplay
two
hepat
stellat
cell
hsc
thought
play
pivot
role
fibrogenesi
within
liver
larg
bodi
evid
support
hypothesi
ang
ii
promot
activ
dedifferenti
cell
myofibroblast
furthermor
ang
ii
encourag
myofibroblast
contract
prolifer
promot
releas
inflammatori
cytokin
well
deposit
extracellular
matrix
ecm
although
ang
ii
receptor
express
liver
receptor
far
abund
thought
respons
ang
effect
studi
use
mice
demonstr
mice
protect
hepat
fibrosi
wherea
mice
wors
fibrosi
great
deal
evid
support
role
ra
hepat
fibrosi
come
anim
studi
use
ace
inhibitor
angiotensin
receptor
blocker
arb
numer
studi
use
varieti
anim
model
demonstr
antifibrot
effect
drug
howev
appear
conflict
observ
report
literatur
exampl
losartan
treatment
fail
influenc
either
liver
injuri
progress
fibrosi
anim
model
steatohepat
nash
editor
note
detail
review
anim
model
nash
written
larter
yeh
later
articl
basic
scienc
miniseri
contrast
studi
similar
model
nash
use
arb
olmesartan
demonstr
reduct
fibrosi
group
avid
interest
drug
part
relat
rel
safeti
human
widespread
use
cardiovascular
renal
medicin
despit
larg
number
anim
studi
rel
pauciti
human
data
support
use
drug
human
liver
diseas
part
could
due
need
perform
multipl
liver
biopsi
histolog
confirm
resolut
fibrosi
outsid
set
recurr
hepat
c
rare
indic
addit
slow
progress
fibrosi
diseas
hepat
c
fatti
liver
diseas
nafld
make
difficult
detect
possibl
benefici
effect
antifibrot
therapi
unless
studi
conduct
number
year
pilot
studi
examin
effect
month
losartan
treatment
liver
fibrosi
chronic
hepat
c
demonstr
signific
decreas
fibrosi
stage
treat
group
compar
control
patient
support
studi
use
candesartan
week
compens
child
b
cirrhot
patient
demonstr
signific
reduct
plasma
hyaluron
acid
level
surrog
marker
fibrogenesi
howev
studi
two
three
serum
marker
fibrosi
use
show
improv
histolog
data
provid
make
difficult
evalu
effect
architectur
chang
number
studi
report
possibl
antifibrot
effect
ra
blocker
patient
hepat
c
one
studi
hepat
c
viru
hcv
patient
mild
fibrosi
treat
losartan
mgday
ursodeoxychol
acid
mgday
wherea
control
receiv
ursodeoxychol
acid
alon
signific
reduct
serum
marker
hepat
fibrosi
transform
growth
factor
type
iv
collagen
losartan
ursodeoxychol
acid
group
signific
chang
fibrosi
score
group
anoth
report
describ
outcom
patient
hepat
c
treat
interferon
ifn
alpha
iu
time
week
month
combin
ace
inhibitor
perindopril
mgday
treatment
accompani
signific
improv
serum
marker
fibrosi
hyaluron
acid
type
iv
collagen
procollagen
histolog
analysi
carri
although
studi
perindopril
monotherapi
group
subsequ
studi
group
demonstr
perindopril
alon
decreas
serum
fibrosi
marker
patient
chronic
hepat
c
addit
interferon
significantli
augment
effect
perindopril
monotherapi
final
retrospect
review
compar
liver
histolog
liver
transplant
patient
recurr
hepat
c
take
drug
n
n
group
take
ra
blocker
less
like
develop
sever
hepat
fibrosi
bridg
fibrosi
cirrhosi
year
transplant
control
group
vs
year
p
vs
year
respect
small
studi
look
ra
blocker
nash
one
studi
n
found
give
losartan
mgday
week
hypertens
patient
nash
reduc
serum
serum
ferritin
aminotransferas
level
five
patient
show
improv
grade
hepat
necroinflamm
studi
design
could
improv
investig
examin
histolog
biochem
marker
placebo
group
subsequ
studi
biopsi
seven
patient
nash
treat
losartan
mgday
week
compar
eight
patient
nafld
act
control
group
treatment
group
show
signific
improv
necroinflammatori
grade
stage
fibrosi
significantli
fewer
activ
hsc
mild
increas
quiescent
hsc
end
week
howev
lack
proper
random
control
group
particular
problem
studi
patient
nash
diseas
improv
respons
chang
lifestyl
fix
chang
hepat
architectur
account
approxim
total
resist
portal
blood
flow
cirrhot
liver
remain
result
revers
dynam
resist
caus
contract
activ
myofibroblast
posit
around
sinusoid
endotheli
cell
within
space
diss
portal
resist
increas
number
factor
includ
distens
portal
venou
system
endotoxemia
oxid
stress
result
releas
mediat
includ
nitric
oxid
dilat
mesenter
system
vasculatur
activ
compensatori
mechan
design
restor
function
blood
volum
result
sodium
water
retent
stimul
sympathet
nervou
system
develop
hyperdynam
circul
cascad
event
contribut
mani
key
featur
complic
advanc
liver
diseas
includ
develop
ascit
edema
hepatoren
syndrom
ra
involv
process
manipul
ra
either
antagonist
classic
pathway
agonist
altern
pathway
therefor
potenti
therapeut
benefit
varic
bleed
one
import
caus
morbid
mortal
patient
portal
hypertens
number
pharmacolog
approach
develop
prevent
treatment
problem
antagonist
lower
portal
pressur
decreas
cardiac
output
constrict
mesenter
vascular
bed
direct
effect
intrahepat
resist
portal
flow
drug
becom
mainstay
treatment
prevent
varic
bleed
howev
patient
achiev
target
reduct
portal
pressur
measur
hepat
venou
pressur
gradient
hvpg
poorli
toler
patient
sever
liver
diseas
result
major
interest
develop
pharmacolog
therapi
lower
portal
pressur
interestingli
interact
ra
inhibit
renin
releas
shown
impact
develop
progress
hepat
fibrosi
contrast
use
either
ace
inhibitor
arb
reduc
portal
pressur
attract
proposit
drug
addit
potenti
benefit
slow
progress
hepat
fibrosi
ang
ii
potent
vasoconstrictor
myofibroblast
deriv
hsc
express
receptor
contract
respons
ang
ii
addit
cirrhot
rat
liver
hyperrespons
ang
ii
increas
portal
pressur
compar
healthi
rat
result
increas
express
receptor
find
interest
given
rel
import
ang
ii
mediat
increas
portal
resist
question
base
studi
hepat
hemodynam
isol
perfus
cirrhot
rat
liver
suggest
ang
vasoconstrict
attenu
cirrhot
liver
follow
persuas
anim
studi
effect
blockad
portal
hypertens
examin
number
human
studi
despit
encourag
initi
studi
show
signific
reduct
portal
pressur
arb
subsequ
studi
fail
confirm
find
schneider
colleagu
report
dramat
reduct
hvpg
losartan
moder
sever
portal
hypertens
patient
mmhg
drop
mean
arteri
pressur
map
find
markedli
differ
subsequ
random
control
trial
compar
hemodynam
effect
losartan
propanolol
given
week
follow
index
varic
bleed
losartan
fail
reduc
hvpg
yet
result
signific
reduct
map
treatment
toler
equival
hemodynam
effect
losartan
corrobor
recent
small
studi
patient
also
found
losartan
affect
hvpg
caus
drop
map
irbesartan
anoth
arb
produc
modest
reduct
portal
pressur
p
random
studi
importantli
howev
associ
signific
arteri
hypotens
signific
renal
impair
patient
studi
plasma
renin
activ
treatment
predictor
patient
would
toler
treatment
explan
advers
effect
ra
known
play
central
role
homeostat
respons
vasodilat
patient
portal
hypertens
ra
togeth
compensatori
system
posterior
pituitari
vasopressin
secret
sympathet
nervou
system
endeavor
restor
circulatori
volum
organ
perfus
induc
vasoconstrict
sodium
water
retent
patient
advanc
cirrhosi
plasma
renin
ang
ii
ace
aldosteron
level
increas
within
kidney
ang
ii
critic
mainten
renal
perfus
pressur
adequ
glomerular
filtrat
rate
gfr
liver
diseas
progress
decreas
effect
circulatori
volum
result
vasoconstrict
glomerular
affer
circul
renal
hypoperfus
fall
gfr
respons
renal
hypoperfus
ang
ii
select
constrict
effer
glomerular
arteriol
restor
glomerular
perfus
pressur
gfr
mainten
adequ
renal
perfus
therefor
ace
depend
furthermor
ace
inhibit
result
rapid
fall
gfr
advers
effect
ra
inhibit
renal
function
patient
advanc
cirrhosi
repres
major
disadvantag
use
class
drug
treatment
portal
hypertens
recent
studi
colleagu
examin
effect
candesartan
treatment
week
compens
child
b
cirrhot
patient
treatment
well
toler
mild
signific
reduct
hvpg
treat
furthermor
patient
treat
achiev
reduct
hvpg
interestingli
chang
hvpg
correl
well
observ
plasma
hyaluron
acid
howev
treatment
group
preselect
patient
exclud
analysi
larg
varic
evid
signific
arteri
hypotens
renal
impair
angiotensin
receptor
blocker
also
studi
portal
hypertens
gastropathi
least
one
studi
report
posit
benefit
use
effect
ace
inhibitor
portal
pressur
also
examin
small
studi
result
gener
disappoint
poor
agreement
studi
number
explan
propos
explain
lack
uniform
result
clinic
studi
investig
benefit
advers
effect
ra
inhibitor
known
genet
polymorph
receptor
gene
gene
respons
cleav
angiotensin
includ
ace
may
confer
variat
respons
drug
led
suggest
genet
test
may
help
determin
patient
like
posit
respons
therapi
addit
chronic
ace
inhibit
may
lead
sustain
ang
ii
suppress
increas
renin
activ
upregul
altern
enzym
hepat
chymas
capabl
gener
ang
ii
ang
furthermor
chronic
use
arb
also
result
elev
ang
ii
level
latter
increasingli
compet
receptor
antagonist
bind
site
receptor
molecul
final
also
claim
respons
ace
inhibitor
arb
current
therapeut
dose
class
drug
may
complet
inhibit
respect
target
date
studi
examin
effect
portal
pressur
combin
therapi
ace
inhibitor
arb
theoret
may
overcom
possibl
issu
ang
ii
reactiv
use
ace
inhibitor
alon
summari
use
ra
inhibitor
reduc
portal
pressur
disappoint
dose
use
clinic
trial
drug
appear
minor
effect
portal
pressur
signific
includ
system
hypotens
renal
impair
complic
use
remind
homeostat
role
ra
play
maintain
map
gfr
vasodil
patient
sever
liver
diseas
base
current
avail
evid
use
either
ace
inhibitor
arb
reduc
portal
pressur
remain
controversi
recommend
outsid
clinic
trial
outlin
increas
evid
classic
altern
ra
upregul
chronic
liver
diseas
recent
suggest
progress
liver
fibrosi
may
influenc
balanc
ace
activ
anim
model
secondari
biliari
fibrosi
human
hepat
c
gene
activ
upregul
fibrosi
worsen
progress
rise
ace
gene
express
coincid
increas
ma
express
togeth
increas
plasma
level
ang
ii
cirrhot
liver
greater
capac
healthi
liver
convert
ang
ii
upregul
gene
protein
express
fig
addit
hepat
product
ang
ii
augment
ace
inhibit
increas
product
presenc
ace
inhibitor
explain
fact
cleav
ace
produc
inact
peptid
fig
inhibit
ace
therefor
increas
lead
increas
net
product
accumul
evid
benefici
role
hepat
fibrosi
provid
studi
examin
effect
ma
receptor
antagonist
treatment
worsen
experiment
liver
injuri
increas
hydroxyprolin
level
infer
ma
receptor
stimul
play
protect
role
liver
fibrosi
compel
evid
benefici
role
come
recent
rat
studi
present
aasld
group
demonstr
infus
bile
rat
attenu
fibrosi
quantifi
use
metavir
fibrosi
score
hydroxyprolin
content
type
collagen
mrna
express
muscl
actin
gene
protein
express
also
reduc
indic
hepat
stellat
cell
activ
inhibit
interestingli
infus
also
inhibit
ace
gene
protein
express
result
downregul
ma
receptor
gene
express
infus
group
also
show
decreas
mrna
express
level
connect
tissu
growth
factor
ctgf
also
known
vascular
endotheli
growth
factor
vegf
two
critic
growth
factor
implic
fibrosi
tissu
repair
first
direct
evid
show
amelior
hepat
fibrosi
evid
studi
delet
mice
support
central
role
regul
fibrosi
liver
diseas
despit
number
report
vasodil
experi
rat
isol
perfus
liver
fail
demonstr
vasodilatori
effect
normal
cirrhot
liver
likewis
experi
isol
vessel
normal
cirrhot
rat
also
fail
show
direct
vasodilatori
effect
peptid
convers
shown
enhanc
vasodilat
aortic
ring
cirrhot
rat
vasodilatori
effect
thought
mediat
increas
product
nitric
oxid
henc
absenc
vasodilatori
effect
cirrhot
rat
liver
could
explain
known
gener
impair
vasodilat
cirrhot
liver
due
endotheli
dysfunct
summari
consider
evid
support
concept
oppos
axe
ra
involv
pathogenesi
chronic
liver
injuri
one
side
aceang
receptor
axi
promot
liver
injuri
deposit
extracellular
matrix
ma
receptor
promot
collagen
degrad
resolut
inflamm
axe
upregul
liver
diseas
presum
balanc
two
system
critic
determin
net
effect
mani
year
research
field
ra
concentr
block
compon
classic
system
attempt
reduc
fibrosi
howev
ace
inhibitor
arb
impact
compon
classic
ra
apart
ang
ii
plasma
renin
activ
ang
level
increas
follow
chronic
therapi
part
explain
phenomenon
angiotensin
ii
reactiv
aldosteron
escap
wherebi
chronic
administr
ace
inhibitor
fail
complet
suppress
either
plasma
ang
ii
aldosteron
product
actual
mechan
underli
phenomenon
remain
elus
although
pathway
involv
enzym
like
chymas
capabl
gener
ang
ii
may
play
import
part
interestingli
ace
inhibitor
arb
profound
impact
altern
system
caus
signific
increas
postul
benefici
effect
observ
arb
ace
inhibitor
mediat
support
activ
gene
express
increas
heart
arb
ace
inhibitor
elev
activ
tissu
would
result
diminish
level
ang
ii
simultan
elev
tissu
thu
tip
ra
balanc
favor
altern
axi
interestingli
studi
other
shown
inhibit
ace
activ
gene
express
would
tend
alter
balanc
two
axe
toward
altern
axi
fig
understand
ra
consider
expand
sinc
discoveri
emerg
evid
support
hypothesi
ra
consist
two
oppos
axe
manipul
ra
either
block
classic
ra
stimul
altern
ra
repres
potenti
target
antifibrot
portal
hypertens
therapi
limit
treatment
may
drug
particularli
impact
arteri
blood
pressur
renal
function
current
therapi
ace
inhibitor
arb
use
cardiovascular
renal
fibrosi
shown
impact
classic
altern
pathway
elev
plasma
level
caus
drug
may
repres
mechan
drug
exert
effect
new
drug
mimic
effect
develop
repres
novel
set
agent
could
use
treatment
hepat
fibrosi
portal
hypertens
one
drug
analog
oral
activ
receptor
agonist
repres
entir
new
class
drug
spawn
latest
insight
complex
contemporari
ra
possibl
novel
therapeut
applic
liver
diseas
